UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000015405 |
|---|---|
| Receipt number | R000017596 |
| Scientific Title | A randomized, phase III trial of sequential capecitabine/5FU plus bevacizumab (Cape/5FU-Bmab) to capecitabine/5FU plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer. |
| Date of disclosure of the study information | 2014/10/14 |
| Last modified on | 2019/02/22 13:07:56 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2014/10/10 15:26:22 | ||
| 2 | Update | 2014/10/14 13:22:54 | Recruitment status |
|
| 3 | Update | 2014/10/14 13:23:36 | Date of disclosure of the study information |
|
| 4 | Update | 2014/11/17 10:17:59 | Organization Organization Name of secondary funder(s) Name of secondary funder(s) |
|
| 5 | Update | 2014/12/05 17:24:00 | Recruitment status |
|
| 6 | Update | 2014/12/07 10:56:58 | Category of Funding Organization |
|
| 7 | Update | 2016/10/11 13:23:59 | Recruitment status |
|
| 8 | Update | 2019/02/22 13:07:56 | Recruitment status Last follow-up date Date of closure to data entry Date trial data considered complete |
